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Down syndrome acute lymphoblastic leukemia, a highly
heterogeneous disease in which aberrant expression of CRLF2 is
associated with mutated JAK2: a report from the International
BFM Study Group
Abstract
We report gene expression and other analyses to elucidate the molecular characteristics of acute
lymphoblastic leukemia (ALL) in children with Down syndrome (DS). We find that by gene expression
DS-ALL is a highly heterogeneous disease not definable as a unique entity. Nevertheless, 62% (33/53)
of the DS-ALL samples analyzed were characterized by high expression of the type I cytokine receptor
CRLF2 caused by either immunoglobulin heavy locus (IgH@) translocations or by interstitial deletions
creating chimeric transcripts P2RY8-CRLF2. In 3 of these 33 patients, a novel activating somatic
mutation, F232C in CRLF2, was identified. Consistent with our previous research, mutations in R683 of
JAK2 were identified in 10 specimens (19% of the patients) and, interestingly, all 10 had high CRLF2
expression. Cytokine receptor-like factor 2 (CRLF2) and mutated Janus kinase 2 (Jak2) cooperated in
conferring cytokine-independent growth to BaF3 pro-B cells. Intriguingly, the gene expression signature
of DS-ALL is enriched with DNA damage and BCL6 responsive genes, suggesting the possibility of
B-cell lymphocytic genomic instability. Thus, DS confers increased risk for genetically highly diverse
ALLs with frequent overexpression of CRLF2, associated with activating mutations in the receptor itself
or in JAK2. Our data also suggest that the majority of DS children with ALL may benefit from therapy
blocking the CRLF2/JAK2 pathways.
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We report gene expression and other analy-
ses to elucidate the molecular characteris-
tics of acute lymphoblastic leukemia (ALL)
in children with Down syndrome (DS). We
find that by gene expression DS-ALL is a
highly heterogeneous disease not definable
as a unique entity. Nevertheless, 62% (33/53)
of the DS-ALL samples analyzed were char-
acterized by high expression of the type I
cytokine receptor CRLF2 caused by either
immunoglobulin heavy locus (IgH@) translo-
cations or by interstitial deletions creating
chimeric transcripts P2RY8-CRLF2. In 3 of
these 33 patients, a novel activating somatic
mutation, F232C in CRLF2, was identified.
Consistent with our previous research, mu-
tations in R683 of JAK2 were identified in
10 specimens (19% of the patients) and,
interestingly, all 10 had high CRLF2 expres-
sion. Cytokine receptor-like factor 2 (CRLF2)
and mutated Janus kinase 2 (Jak2) cooper-
ated in conferring cytokine-independent
growth to BaF3 pro-B cells. Intriguingly, the
gene expression signature of DS-ALL is
enriched with DNA damage and BCL6 re-
sponsive genes, suggesting the possibility
of B-cell lymphocytic genomic instability.
Thus, DS confers increased risk for geneti-
cally highly diverseALLs with frequent over-
expression of CRLF2, associated with acti-
vating mutations in the receptor itself or in
JAK2. Our data also suggest that the major-
ity of DS children with ALL may benefit from
therapy blocking the CRLF2/JAK2 path-
ways. (Blood. 2010;115:1006-1017)
Introduction
Children with Down syndrome (DS) have a higher rate of acute
lymphoblastic leukemia (DS-ALL). DS-ALLs are mostly of B-cell
precursor (BCP) origin and similar in the age of diagnosis and
immunophenotype to high hyperdiploid (HD) or TEL-AML1 ALLs,1
the 2 most common genetic subtypes of childhood ALL. Given that
these cytogenetic abnormalities are less frequent in DS-ALL,2 the
existence of unique collaborating somatic genetic events in DS-
ALL, similar to the GATA1 mutation in DS-acute megakaryoblastic
leukemia,3 has been postulated.
We and others reported the presence of somatic activating mutations
in JAK2 in approximately 20% of DS-ALLs.4-6 Similar mutations are
present in approximately 10% of high-risk ALLs in non-DS children,
corresponding to approximately 3% of unselected childhoodALLs.7 We
hypothesized that the mutated Janus kinase 2 (JAK2) may cooperate
with a type I cytokine receptor that is aberrantly expressed in DS-ALL.4
To characterize additional molecular abnormalities in DS-ALL,
we performed genomic analysis of a large group of DS-ALLs. This
analysis reveals, next to a striking heterogeneity of these leuke-
mias, an aberrant expression of the cytokine receptor CRLF2 in
62% of the patients, associated with somatic activating mutations
in JAK2 or in the receptor itself.
Methods
Patient samples
RNA and DNA were derived from diagnostic bone marrow samples of
children with DS and BCP-ALL enrolled on treatment protocols with an
informed consent and approval of the ethics committees of all participating
institutions in accordance with the Declaration of Helsinki. Samples were
Submitted August 5, 2009; accepted November 1, 2009. Prepublished online
as Blood First Edition paper, November 24, 2009; DOI 10.1182/blood-2009-08-
235408.
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anonymized for the study. Patients’ clinical data are described in supple-
mental Tables 1 and 2 (available on the Blood website; see the Supple-
mental Materials link at the top of the online article). Seventy-six of these
patients were included in our previous publication describing the JAK2
mutations in DS-ALL.4 The study was approved by the Israeli Health
Ministry Ethic committee (approval no. 920070771).
Genomic studies
RNA processing and hybridization to Affymetrix arrays were performed
according to the manufacturer’s instructions and as previously published.8,9
Only specimens containing more than 70% blasts were included. There
were 4 datasets obtained by different teams as summarized in Table 1.
Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) is the
main dataset used for gene expression analysis, comprising 97 diagnostic
ALL samples: 25 DS-ALL, and 72 non–DS-ALL samples, described in
Table 1. The additional 3 datasets were used for validations. The primary
gene expression data files have been deposited in National Center for
Biotechnology Information’s Gene Expression Omnibus (GEO; http://
www.ncbi.nlm.nih.gov/geo/)11 (GEO series accession no. GSE17459).
Genomic DNA from 42 diagnostic bone marrow ALLs and 34 paired
remission samples were genotyped with Affymetrix GeneChip Human
Mapping 100K set (Affymetrix) according to the manufacturer’s directions.
See supplemental data for details.
Mutation analysis
Mutation analysis was performed as we previously described.4,12 CRLF2
(NM_022148.2) primers are described in supplemental Table 3.
Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) was per-
formed using Applied Biosystems TaqMan Gene-Expression Assays (CRLF2
Hs_00845692, GAPDH Hs_99999905) according to the manufacturer’s
instructions. Each sample was run in triplicate. The endogenous control
gene was GAPDH.
FISH
Fluorescence in situ hybridization (FISH) for detection of IGH@-CRLF2
translocation or the presence of a microdeletion upstream to CRLF2 was
performed as described.13
Flow cytometric analysis
Flow cytometric analysis (FACSCanto II [Becton Dickinson]; FlowJo
software [TreeStar]) was performed on primary cryopreserved ALL cells
after the first xenotransplantation in Nod/LtSzScid interleukin-2 (IL2)–
null mice. Antibodies used were anti–cytokine receptor-like factor 2
(CRLF2; clone 1D3, ab48482; Abcam), goat anti–mouse Alexa Fluor 488
(Invitrogen), anti-IL7RA Alexa 647 (CD127, clone HIL-7R-M21; BD),
anti-CD19 phycoerythrin (clone LT19, MCA1940; AbD Serotec), and
7-amino-actinomycin D (AbD Serotec). All samples were gated on the
viable (7-amino-actinomycin D–negative) and leukemic (CD19) popula-
tion before analysis of CRLF2 and IL7RA. For the calculation of delta
mean fluorescence intensity (MFI), background nonspecific staining was
evaluated in populations gated by CD19, comparing tubes with or without
anti-CRLF2 antibodies. This background MFI was similar to the MFI of
CRLF2-negative populations in normal human blood.
Plasmid construction
The FLAG-mJak2 wild-type and R683S were cloned into the pHRSINCSGW
lentivirus,12 which carries spleen focus-forming virus (SFFV) promoter and an
emerald green fluorescent protein reporter. pMX-Puro-hCRLF2 was used as a
template for the generation of CRLF2 mutations by site-directed mutagenesis
(QuikChange-II-XL; Stratagene).
Cell lines
BaF3 cells were cultured in RPMI-1640 containing 10% fetal calf serum
and 10% WHEI-3B conditioned media as a source of interleukin-3.
Parental BaF3 cells were transduced with pMX-Puro-hCRLF2,14 and
hCRLF2-expressing cells were selected with puromycin (2 g/mL). Paren-
tal BaF3 and BaF3-CRLF2 cells were transduced with the appropriate
Jak2-expressing vector and green fluorescent protein–positive cells were
sorted by flow cytometry 3 to 4 days later.
BaF3 proliferation assays and Western blotting
BaF3 proliferation assays and Western blotting were performed as de-
scribed before.4 Antibodies used were anti-JAK2 (C-20; Santa Cruz
Biotechnology), anti–signal transducer and activator of transcription 5
(STAT5), anti–phospho-JAK2 Tyr1007 (Cell Signaling Technology), anti–
phospho-STAT5 Tyr694 (Epitomics), anti–human thymic stromal lympho-
poietin (hTSLPR; AF981; R&D Systems), anti–FLAG-M2, and anti–-
tubulin (Sigma-Aldrich).
Pharmacologic inhibition of JAK2
BaF3 cells expressing Jak2 R683S and BaF3/CRLF2 cells expressing
wild-type (wt) or R683S Jak2 were cultured without cytokines in different
concentrations of JAK inhibitor I (Calbiochem). Controls were BaF3/EpoR
cells expressing BCR-ABL. Viable cells were counted after 72 hours. Data
from 3 independent experiments were combined for analysis. We calculated
the normalized viability by dividing the cell number at each inhibitor
concentration by the cell number with vehicle alone.
Bioinformatics
Gene expression preprocessing is described in supplemental Methods.
Combining probe sets of the same gene. For those genes that were
represented by more than one probe set, we used, when needed, a
combination procedure to create a single representation of a gene’s
expression (supplemental Methods).
GSEA. The first ingredient of Gene Set Enrichment Analysis (GSEA)15
is a list of genes (L), ranked by some attribute (A), ordered from low to high
values of A. The second ingredient is a set of genes (S) that is a subset of L.
GSEA aims at answering whether the members of S are randomly
distributed along the ranked list L, or whether they are skewed toward one
of the sides. For details see supplemental Methods and Subramanian et al.15
Refining DS-ALL profile genes. The preliminary DS-ALL profile
gene list, which was constructed using the AIEOP dataset, was narrowed
down using GSEA15 to select genes that show consistent expression pattern
in at least 2 of the other 3 datasets (Table 1). We used the up-regulated members
Table 1. Description of the gene expression datasets analyzed
Dataset symbol
No. samples
PlatformTotal DS-ALL HD TEL-AML1 Other
AIEOP* 97 25 26 29 4 E2A-PBX1, 6 MLL, 7 BCR-ABL Affymetrix HG-U133 Plus 2.0
ICH 15 6 5 4 Affymetrix HG-U133 Plus 2.0
BFM8* St Jude10† 36 7 12 17 Affymetrix HG-U133A
IL† 27 11 10 6 Affymetrix Exon 1.0 ST
AIEOP indicates Associazione Italiana Ematologia Oncologia Pediatrica; ICH, Institute Child Health; BFM, Berlin-Frankfurt-Munster; and IL, Israel.
*IL is partially overlapping with AIEOP (5 DS-ALLs) and BFM (4 different DS-ALLs).
†We used a subgroup of HD and TEL-AML1 samples from St Jude dataset.
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of the preliminary DS-ALL genes as our set S (see “Bioinformatics”) and the
genes of 1 of the other 3 experiments constituted L. The genes of L were ordered
according to their differential expression in DS versus the rest of the samples (see
Refining DS-ALL profile genes in supplemental Methods). The process was
repeated for each of the 3 datasets and for the down-regulated genes, yielding for
each case genes that were identified as consistently up-regulated (or down-
regulated) in the AIEOP dataset and the other dataset tested (Figure 2A).
Results
Marked heterogeneity of DS-ALLs revealed by unsupervised
gene expression analysis
We first explored the extent of similarity between DS-ALLs and
other defined BCP-ALL genetic subtypes using in the analysis the
1500 probe sets with the highest standard deviation among the
AIEOP samples. Two unsupervised analysis algorithms were used:
Sorting Points Into Neighborhoods (SPIN),16 which places samples
with similar expression profiles near each other (Figure 1A), and
Principal Component Analysis (PCA; MATLAB 7.4 software
[Mathworks]; Figure 1B). Both gave similar results.
In agreement with previous studies,10 unsupervised analysis of
gene expression tends to group the pediatric ALL samples accord-
ing to their genetic subtypes. As can be seen in the Euclidian
distance matrix in Figure 1A, the ALL subgroups that are the most
homogenous (exhibiting high similarity of samples of the same
subtype) are E2A-PBX1–positive ALL and MLL-AF4–positive
ALL, followed by TEL-AML1–positive ALL. HD-ALL samples are
also grouped together, but are relatively more distant from each
other than the E2A-PBX1, MLL-AF4, and TEL-AML1 samples.
Although BCR-ABL ALLs are clustered together, they are less
homogeneous, consistent with previous reports.10
In contrast, DS-ALLs are very heterogeneous (Figure 1A-B).
Approximately half are grouped together, relatively close to both
BCR-ABL and HD-ALL. However even here, individual DS
samples are further separated from each other than a typical pair of
samples within the other ALL subtypes (Figure 1A-B). The other
half are grouped with other ALL subtypes: 6 with TEL-AML1,
6 with HD, 2 with BCR-ABL, and 1 with E2A-PBX1. Of these
15 DS-ALLs, only 3 carried the chromosomal translocation of the
subtype of ALL to which they are most similar (1 E2A-PBX1,
2 TEL-AML1) and only 1 DS-ALL sample was found to be also
HD. Even the 5 DS-ALL samples with somatic mutations in JAK2
(blue boxes below Figure 1A and black circles at Figure 1B) are not
clustered together.
This unsupervised gene expression analysis reveals that DS-
ALLs are markedly less homogenous than the other ALL genetic
subtypes. It suggests that DS is a predisposing condition to several
genetic subtypes of B-cell precursor ALLs, and that unlike the
myeloid leukemia of DS should not be considered as a unique
molecular entity.
Genomic analysis of DS-ALL
We performed 100-K single nucleotide polymorphism array analy-
sis of 34 paired diagnosis and remission samples (15 DS-, 9 HD-,
and 10 TEL-AML ALLs, supplemental Methods). Copy number
and loss-of-heterozygosity analyses (supplemental Figure 3; supple-
mental Table 10) generally confirm previous reports5,17 that dele-
tions are more common in DS and TEL-AML1 compared with
HD-ALLs. The frequency of deletions in genes regulating normal
B-lymphoid development (supplemental Table 9) in DS-ALL was
53%, slightly higher than the 40% reported for of BCP-ALL.18
Recently, deletions in the IKZF1 gene were reported in the majority
of patients with BCR/ABL and “BCR/ABL-like” ALL.19,20 Because
most of these deletions involve only a subset of exons (most
commonly exons 4-7), the 100-K single nucleotide polymorphism
platform is inadequate to detect these abnormalities. Therefore,
38 additional diagnostic DS-ALL specimens were screened for
IKZF1 deletions by PCR analysis as previously reported.21 Monoal-
lelic IKZF1 deletions were identified in 9 patients (24%; supplemen-
tal Table 8 and supplemental Figure 3). Thus the frequency of
deletions in B-cell differentiation genes, including IKZF1, in
DS-ALL is similar to other non–BCR-ABL subtypes of BCP-ALL.
DS-ALL gene expression profile
We hypothesized that, despite their heterogeneity, DS-ALLs share
a common gene expression signature. We reasoned that by
comparing the gene expression in DS-ALL to the relatively similar
groups, HD and TEL-AML1, we could potentially isolate the
“DS-ALL” characteristics from the other ALL characteristics that
might be similar between these groups. In addition, the analysis
was done in a way that only genes that differentiate DS from
TEL-AML1 and from HD-ALLs are depicted. The fact that
TEL-AML1 and HD-ALLs have dissimilar expression profiles
(denoted by dark red entries in Figure 1A) helps to identify genes
that characterize DS-ALL, and not one of the groups to which it
is compared.
We first identified probe sets that had significant differential
expression in DS-ALL samples, compared with both HD and
TEL-AML1 ALLs in the AIEOP dataset (supplemental Methods).
Figure 1. Unsupervised analysis of the AIEOP dataset.
(A) Samples’ Euclidian distance matrix. The color in each entry
(y,x), where x,y 1, . . . , 97 (the number of samples), represents
the Euclidian distance between the expression profiles of samples
x and y. It was measured after centering and normalization of each
sample’s expression, using 1500 probe sets with highest standard
deviation. The samples are ordered by SPIN along both the x-axis
and y-axis. The color bars next to both axes represent the different
ALL subtypes, listed on the right of the figure. The blue marks at
bottom specify DS-ALL samples with mutant JAK2 (J2m), and the
red marks specify samples with high CRLF2 expression levels
(CRLF2) (see “Aberrant expression of the cytokine receptor
CRLF2 in DS-ALLs” section on CRLF2). (B) Projection of all
samples onto the first 3 principle components of the expression.
DS indicates Down syndrome ALL; J2m, Down syndrome ALL
with mutated JAK2 R683; HD, high hyperdiploid; TEL, TEL-AML1;
BCR, BCR-ABL; E2A, E2A-PBX1; and MLL, MLL-AF4.
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This “preliminary DS-ALL profile” consisted of 792 genes up-
regulated and 535 genes down-regulated in DS-ALL. To check
consistency with each of the other 3 gene expression datasets
(“BFM,” “ICH,” and “IL”), we performed GSEA22 separately on
each of the 3. A representative enrichment analysis is shown in
Figure 2A; here the genes are ordered according to their DS-ALL
differential expression in the ICH dataset (used as the list L;
“Bioinformatics”), and the 535 genes down-regulated in DS-ALL
are used as the set S, tested for enrichment. Six such analyses
showed significant enrichment of the preliminary gene lists (both
up- and down-regulated) obtained from AIEOP, in the other
3 datasets (Table 2). We refined our AIEOP-based lists by including
only genes that showed consistent expression patterns in at least
2 of the 3 other datasets. The “refined DS-ALL profile genes”
(Figure 2B) consists of 152 up-regulated and 199 down-regulated
genes (supplemental Tables 4-5).
Pathway analysis and BCL6 signature
To identify molecular pathways that showed differential expression
in the refined DS-ALL profile, we interrogated the DAVID
database23 of Gene Ontology functional categories.24 Constituent
genes of 8 pathways were significantly (false discovery rate [FDR]
 10%) overrepresented in the DS-ALL expression profile (Table
3 and supplemental Table 6). The most enriched pathway (P .001)
is “Response to DNA damage stimulus”: 10 of the 341 genes
assigned by DAVID to this pathway are down-regulated and 6 are
up-regulated in DS-ALL. One of the up-regulated genes is BCL6,
with a mean fold change of 1.46 in DS-ALL compared with non
DS-ALL (supplemental Table 4). BCL6 is a transcription factor
expressed primarily in mature B cells at the germinal centers,
where it facilitates immunoglobulin (Ig) affinity maturation by
repressing the DNA damage response. It is also a known oncogene
in diffuse large B-cell lymphomas.25,26
To search for evidence for BCL6 activity in the DS-ALL gene
expression profile, we used the Oncomine (http://www.oncomine.
org)27,28 database, in which cancer gene expression signatures
derived from different expression analyses are stored as molecular
concept maps. These are lists of differentially expressed genes
between 2 logical groupings of normal or malignant human tissue
or cell lines. We tested BCL6 direct targets and each of the
24 Oncomine molecular concept maps that involve BCL6 (supple-
mental Table 7) for enrichment in DS-ALL up- and down-regulated
genes, and 8 of these 25 gene groups passed at false discovery rate
(FDR)29 of 15% (Table 4). These include the target genes of
BCL6,32 genes modified by ectopic expression of BCL6 in
lymphoblastoid B cells,30 and the gene expression signature of
B-cell lymphomas with oncogenic activation of BCL6.31 Hence the
targets and pathways downstream to BCL6 in lymphomas and
mature B cells are modified in the DS-ALL expression profile.
Aberrant expression of the cytokine receptor CRLF2 in
DS-ALLs
We have previously hypothesized that a cytokine receptor may be
aberrantly expressed in DS-ALL and cooperate with JAK2 carrying
Figure 2. DS-ALL gene expression profile. (A) GSEA analysis on ICH dataset. Genes are ranked (bottom of panel, gray) according to their expression in DS-ALL samples
versus the rest of the samples, by GSEA, using the default parameters. The members of a gene set S (here, the set of 535 genes down-regulated in DS-ALL, AIEOP data) are
tested: are they randomly distributed in the ranked gene list, or primarily found at the top or bottom? Occurrences of members of the gene set S in the ranked gene list are
shown as vertical black lines above the ranked signature. The green curve and upper y-axis represent the enrichment score (ES) as a function of the number of ranked genes
tested for enrichment of gene set S. See supplemental Methods for full details. (B) Expression levels of the genes from the refined DS-ALL lists, measured on the AIEOP
dataset. Four hundred twenty-three probe sets that belong to the refined DS-ALL profile gene lists are centered and normalized. Values for each individual case are
represented by a color, with red representing deviation above the mean and blue representing deviation below the mean. The colors along the x-axis represent the different ALL
subtypes, listed on the right of the plot. DS indicates Down syndrome ALL; HD, high hyperdiploid; TEL, TEL-AML1; BCR, BCR-ABL; E2A, E2A-PBX1; and MLL, MLL-AF4.
Table 2. GSEA for genes of the DS-ALL expression signature,
identified from the AIEOP dataset, in 3 other datasets
Enrichment
score Nominal P FDR q-value
DS-ALL up-regulated genes
ICH dataset 0.437993 .010 0.008979
IL dataset 0.361621 .035 0.022851
BFM dataset 0.344479 .002 0.009101
DS-ALL down-regulated genes
ICH dataset 0.50601554 .006 0.012959
IL dataset 0.5008136 .012 0.006397
BFM dataset 0.55240697 .002 0.001131
Table 3. Gene ontology pathways overrepresented in the differential
DS-ALL signature
Gene ontology group Size P FDR, %
GO:0006974 response to DNA
damage stimulus
16  .001 0.77
GO:0006397mRNA processing 13 .002 2.80
GO:0015031 protein transport 24 .002 3.30
GO:0008104 protein localization 26 .002 3.70
GO:0046907 intracellular transport 24 .003 4.40
GO:0065003macromolecular
complex assembly
20 .004 5.80
GO:0051649 establishment of
cellular localization
27 .005 7.60
GO:0043067 regulation of
programmed cell death
19 .006 9.10
For details, see supplemental Table 6.
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the “lymphoid” mutation in R683.4 Examination of the DS-ALL
expression signature (supplemental Table 4) reveals that the third
most differentially expressed gene is CRLF2 (cytokine receptor-
like factor 2, TSLPR) located at the pseudoautosomal region of the
sex chromosomes. As depicted in Figure 3A, increased expression
of CRLF2 was noted in 23 (62.1%) DS-ALLs of 37 samples that
were hybridized to U133 family of arrays (CRLF2 is not repre-
sented on the exon arrays used in the IL dataset), compared with
other ALL subtypes (see supplemental Methods). CRLF2 expres-
sion along DS-ALL versus all other ALL subtypes yielded t test
P values less than .001 for AIEOP, BFM, and ICH datasets.
CRLF2 is known to dimerize with IL7RA to form the het-
erodimeric receptor for thymic stromal lymphopoietin (TSLP).33
Whereas CRLF2 is aberrantly expressed in DS-ALLs (Figure 3A),
expression of IL7RA is similar in the different ALL subtypes
(Figure 3B).
To validate the findings of the expression arrays and to analyze
additional DS-ALL samples, we measured the expression of
CRLF2 by qRT-PCR in 32 patients (Figure 3C). Microarray data
were available for 16 of these cases. The qRT-PCR confirms the
CRLF2 expression levels seen in the arrays (Pearson correla-
tion 0.85, P  .001). In 2 patients’ CRLF2 expression was
analyzed in RNA derived from diagnostic and remission bone
marrows and was seen only in the diagnostic sample. In one
patient, similar CRLF2 expression levels were seen in bone marrow
samples from diagnosis and relapse (supplemental Figure 2).
Altogether, 33 (62.3%) of 53 DS-ALL patients analyzed by either
qRT-PCR or microarrays overexpressed CRLF2. The surface
expression of the CRLF2 protein was also verified on 4 samples by
flow cytometry (Figure 3D). IL7RA is also expressed on the
leukemic blasts independent of CRLF2 expression.
Recently, Russell et al13 reported aberrant expression of CRLF2
caused by either chromosomal translocations to the IGH@ locus or
interstitial deletions upstream to CRLF2 juxtaposing CRLF2 with
the P2RY8 regulatory elements in approximately 5% of childhood
ALLs. To examine whether the increased CRLF2 expression in
our specimens was caused by the same genomic aberrations,
12 available diagnostic DS-ALL samples overexpressing CRLF2
were analyzed by FISH (Figure 4A). IGH@ translocations were
seen in 4 specimens and interstitial deletions in 7. In the remaining
sample (no. DS-32; supplemental Table 2), in which the CRLF2
expression level was just above the threshold, the FISH pattern of
CRLF2 appeared normal. Further evidence supporting the presence
of the deletions is provided by a statistically significant inverse
correlation between CRLF2 and P2RY8 expression (P  .02,
Figure 4B).
To test whether the deletion caused a fusion between the P2RY8
and CRLF2, we performed RT-PCR with primers derived from both
genes (supplemental Table 3). A transcript fusing the first noncod-
ing exon of P2RY8 and the first exon of CRLF2 prior to the ATG
was detected in the 2 DS patients with the deletion detected by
FISH but not in the patient with the IgH@ translocation (Figure
4C). A similar chimeric transcript was described in a single patient
with splenic lymphoma, fusing P2RY8 to SOX5 resulting in
overexpression of SOX5.34 We extended the analysis and identified
the chimeric transcript in 7 of 10 patients with overexpression of
CRLF2 and in none of 8 samples with no expression of CRLF2
(supplemental Table 2). Thus, consistent with the FISH findings,13
the interstitial deletion is more common than the IgH@ translocation.
To explore the effect of CRLF2 on gene expression, we
compared the 30% of DS-ALLs with the highest CRLF2 expres-
sion and the 30% of DS-ALLs with the lowest CRLF2 expression
in the AIEOP database. Only 5 probe sets passed FDR of 30%, with
CRLF2 being 1 of the 5 (Table 5). This is consistent with the
finding that samples that overexpress CRLF2 (red marks in Figure
1A) do not cluster separately from DS-ALLs that do not express
CRLF2. Interestingly, the IGJ gene that differentiates these 2 groups
(fold change, 36.4; Table 5) is also the most differentiating gene
between DS-ALL and non–DS-ALL in our datasets (supplemental
Table 4).
Clinical significance of CRLF2 expression in DS-ALL
Clinically, children with high/medium expression of CRLF2 were
diagnosed younger (Table 6) than children with no/low expression
of CRLF2 (5.56 vs 9.87 years, P  .004).
No significant differences between the 2 groups regarding their
sex or white blood cell count at diagnosis were found. Patients
expressing CRLF2 tended to have a lower probability for event-
free survival (supplemental Figure 4, P  .12 log-rank test).
Cooperation between JAK2 R683 mutations and CRLF2
aberrant expression
Among the 53 DS-ALL samples for which CRLF2 expression was
available, 10 had somatic mutations in JAK2 R683. We identified
chimeric P2RY8-CRLF2 transcripts in 3 additional patients with
JAK2 R683 mutations (supplemental Table 2). Thus all mutations
occurred in specimens with aberrant expression of CRLF2, support-
ing our initial hypothesis that CRLF2 may act as type I cytokine
receptor for mutated JAK2.
To examine whether CRLF2 and mutated JAK2 cooperate, we
generated BaF3 cells that express hCRLF2 (BaF3-CRLF2) and
transduced both BaF3 and BaF3-CRLF2 cells with wild-type
mJak2-FLAG, R683S mJak2-FLAG, and empty vector. As de-
picted in Figure 5A, there was synergism between CRLF2 and both
wt Jak2 and R683S mutated Jak2, with the best cytokine-
independent growth observed in cells expressing CRLF2 and the
mutated Jak2. These functional effects on cell growth are reflected
Table 4. Enrichment of BCL6-related gene expression signatures
and direct targets in DS-ALL profile genes (FDR< 15%)
Size P Q-value
Oncomine “Molecular Concepts” enriched in
DS-ALL up-regulated genes
EREB lymphoblastoid cell line BCL6
transfection top 10% overexpressed30
17 .004 0.093
Ramos Burkitt lymphoma cell line BCL6 pest
mutant top 5% underexpressed in anti-IgM30
11 .011 0.138
Lymphoma BCL6 break top 5%
overexpressed31
11 .019 0.138
Lymphoma BCL6 break top 10%
overexpressed31
17 .022 0.138
BCL6 direct targets32 11 .030 0.147
Oncomine “Molecular Concepts” enriched in
DS-ALL down-regulated genes
Lymphoma BCL6 break top 10%
underexpressed31
36  .001 0.001
EREB lymphoblastoid cell line BCL6
transfection top 10% underexpressed30
26  .001 0.001
Lymphoma BCL6 break top 5%
underexpressed31
20 .001 0.008
1010 HERTZBERG et al BLOOD, 4 FEBRUARY 2010  VOLUME 115, NUMBER 5
IL7RA
5
6
7
8
9
10
i   AIEOP
L
o
g
2 
E
xp
re
ss
io
n
D
S
H
D
T
E
L
B
C
R
E
2A
M
L
L
5
5.5
6
6.5
7
7.5
8
8.5
ii   BFM
D
S
H
D
T
E
L
5
6
7
8
9
10
11
iii   ICH
D
S
H
D
T
E
L
BA CRLF2
3
4
5
6
7
8
i    AIEOP
L
o
g
2 
E
xp
re
ss
io
n
D
S
H
D
T
E
L
B
C
R
E
2A
M
L
L
4
5
6
7
ii  BFM
D
S
H
D
T
E
L
5
6
7
8
9
10
11
iii      ICH
D
S
H
D
T
E
L
D
C
Figure 3. CRLF2 expression in DS-ALL. (A) CRLF2 expression in the AIEOP (i), BFM (ii), and ICH (iii) datasets. The y-axis represents CRLF2 log basis 2 expression. The
x-axis represents the different ALL subtypes. Each point corresponds to a sample. The black line in each ALL subtype is the CRLF2 mean (log basis 2) expression in this
subtype. The height of the blue rectangle in each ALL subtype is the measured standard deviation of CRLF2 (log basis 2) expression. DS-ALL versus all other ALL yielded t test
P values of less than .001 for AIEOP (i), BFM (ii), and ICH (iii). DS indicates Down syndrome ALL; HD, high hyperdiploid; TEL, TEL-AML1; BCR, BCR-ABL; E2A, E2A-PBX1;
and MLL, MLL-AF4. (B) IL7RA expression in the AIEOP (i), BFM (ii), and ICH (iii) datasets. There are no statistically significant differences between DS-ALLs and
non–DS-ALLs. (C) Verification of CRLF2 expression levels by qRT-PCR. Bars represent qRT-PCR CRLF2 expression levels (left, y-axis: fold change relative to patient DS-12,
the lowest CRLF2 expressor). Rhombuses represent gene expression array CRLF2 expression levels (right, y-axis: log basis 2). Red bars represent patients with JAK2 R683
mutation; blue bars, patients with CRLF2 F232C mutation (Figure 6). Rem indicates CRLF2 levels of available remission samples (patients DS-19 and DS-20); CONT, control
CRLF2 expression levels in peripheral white blood cells of healthy donors. (D) CRLF2 and IL7RA protein expression on the surface of DS-ALL leukemic blasts. (Left panel)
Delta mean fluorescence intensity of the signal detected by flow cytometry using specific anti-CRLF2 antibodies compared with background unspecific staining (“Flow
cytometric analysis”), indicating an apparent association between the JAK2 mutational status and the level of expression of CRLF2 on DS-ALL blasts. (Right panel) Dot plot of
2 representative CRLF2 and IL7RA costainings. IL7RA is highly expressed on leukemic blasts independent of JAK2 mutational status and level of CRLF2 expression in all
cases examined. wt indicates wild-type; mut, mutant; het, heterozygous; and hom, homozygous.
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in protein analysis of the JAK/STAT pathway (Figure 5B).
Interestingly, despite identical levels of CRLF2 at the time of
transduction, the levels of CRLF2 were consistently higher in cells
transduced with Jak2 compared with empty vector or parental cells.
Examination of Stat5 and Jak2 phosphorylation 5 hours after
cytokine withdrawal reveals that when CRLF2 was expressed,
phosphorylation levels in cells transduced with wt Jak2 were
increased, whereas no change was observed in the already high
ba
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Figure 4. Genomic analysis of CRLF2 aberrations. (A) FISH analysis of DS-ALL expressing CRLF2 (i-ii) IGH@ CRLF2 translocation, patient DS-85: (i) Metaphase showing
a positive result with the LSI IGH@ break-apart rearrangement probe (Abbott Molecular): normal chromosome 14 (yellow arrow) derived chromosome 14 (red arrow), derived X
chromosome (green arrow). (ii) Interphase nucleus from the same patient hybridized with the homegrown CRLF2 probe showing a split signal pattern, 1R1G1F, confirming its
involvement in the translocation (1 fusion signal [yellow arrow], 1 red signal [red arrow], and 1 green signal [green arrow]). (iii-iv) CRLF2 microdeletion, patient DS-82.
(iii) Interphase nucleus hybridized with the IGH@ probe showing the normal 0R0G2F signal pattern confirming the presence of 2 normal copies of IGH@. (iv) Interphase
nucleus from the same patient hybridized with the homegrown CRLF2 probe showing the deletion of the green portion of the probe (1 red signal [red arrow] and 1 fusion signal
[yellow arrow]) denoting the presence of a centromeric interstitial deletion. (B) CRLF2 and P2RY8 expression in DS-ALL samples. Centered and normalized log basis
2 expression of CRLF2 and P2RY8 along DS-ALL samples in AIEOP dataset. Values for each individual case are represented by a color, with red representing deviation above
the mean and blue representing deviation below the mean. The samples are sorted using SPIN. Pearson correlation between CRLF2 and P2RY8: 0.45 (P  .02).
(C) Detection of the P2RY8-CRLF2 fusion transcript. (i) Schematic representation of the deletion breakpoint region at the telomeric end of chromosome X/Y with gene
locations. The dashed lines represent the genomic deletion leading to the fusion of the first noncoding exon of P2RY8 and to the first (coding) exon of CRLF2. (iii) RT-PCR
experiments on cDNA of DS patients. (Lanes 1-3) DS diagnostic ALL samples (DS93 and DS82 with FISH determined deletion and DS92 with FISH determined IgH@
translocation). (Lane 4) Blank. The 3 patient samples were positive for ABL amplification (not shown). Primer sets used are (A) P2RY8 F01/CRLF2 R01; (B) P2RY8 F01/
CRLF2 R02; (C) P2RY8 F01/CRLF2 R03 shown on the sequence on the left (ii). Chimeric transcripts are present in the first 2 lanes of each set. (ii) Nucleotide sequencing of the
largest PCR fragment confirming the fusion transcript; vertical lines indicate exon boundaries; the arrowhead indicates the P2RY8/CRLF2 transcript junction. As seen, the
fusion is just upstream to the ATG of CRLF2. Reference sequences are P2RY8-001 (ENST00000381297) and CRLF2-001 (ENST00000400841). Boxed sequence around the
transcript junction is represented in the electropherogram on the right lower side (iv).
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phosphorylation levels in cells expressing the mutated Jak2. The
marked advantage in cytokine-independent growth rate of cells
coexpressing CRLF2 and R683S Jak2 despite similar Stat5
phosphorylation may indicate the involvement of additional
signaling pathways.
To test whether the cells expressing CRLF2 and/or either wt or R683
mutated Jak2 depend on activated JAK signaling, we incubated BaF3
cells transduced with the different vectors cultured without IL3 in the
presence of different concentrations of JAK inhibitor l (Figure 5C).
Although BaF3 cells transduced with CRLF2/Jak were more sensitive
to the inhibitor compared with the control cells expressing BCR-ABL
(P .04, analysis of variance), the cells expressing CRLF2 and mutated
Jak2 were the least sensitive.
Activating mutations of CRLF2 in DS-ALL
To identify additional events leading to CRLF2 activation, we
screened 87 diagnostic DS-ALL samples for mutations in CRLF2
(Figure 6). In addition to polymorphisms V136M and V244M that
were present also in remission samples and in healthy controls, we
identified in 3 patients a somatic mutation replacing phenylalanine
232, located at the juxtamembranous domain, with cysteine
(F232C). Genomic data were available for one of the patients
(DS-97) who displayed the P2YR8-CRLF2 transcript. Although
F232C induced constitutive Stat5 phosphorylation in cytokine-
deprived BaF3 cells (Figure 6E), it did not provide a consistent
survival advantage. Whereas during the first few days after
cytokine withdrawal more cells expressing F232C CRLF2 were
alive compared with cells expressing wt CRLF2, at day 7 almost all
BaF3 cells were dead (not shown). To examine the collaboration
with wt Jak2, BaF3 cells stably expressing wt Jak2 were transduced
with retroviral vectors expressing either wt CRLF or F232C
CRLF2 (Figure 6D-E). In the presence of exogenous wt Jak2, there
was an approximately 15-fold increase in the growth rate of cells
expressing the mutant CRLF2 compared with those expressing wt
CRLF2 (P  .02, paired t test). Together these observations
demonstrate that the F232C CRLF2 activates Jak/Stat signaling
and cooperates with Jak2 to provide significant growth advantage
in a cytokine-deprived environment.
Discussion
Here we report the results of a genome-wide study of DS-ALL
based on a dataset of unprecedented size. Unexpectedly, the
molecular phenotype obtained by gene expression profiling is
strikingly less homogeneous in DS-ALL than any of the common
genetic subtypes of childhood BCP-ALLs. However, despite this
heterogeneity, we describe a major feature that is shared by up to
two-thirds of the patients—the aberrant expression of the wt or
mutated cytokine receptor CRLF2 and its association with muta-
tions in JAK2.
That DS-ALL is less uniform than the specific DS-associated
myeloid leukemia has been suggested by a large cytogenetic study
performed by the International BFM Study Group.2 However,
neither that study nor the genomic analysis reported here or
previously5,17 explains the level of inhomogeneity in gene expres-
sion. Even those DS-ALLs that clustered together were not similar
to each other. Such heterogeneity suggests that unlike the common
aberrations of childhood ALL (TEL-AML1, hyperdiploidy, E2A-
PBX1, etc), constitutional trisomy 21 is not a typical initiating
event. Rather, DS is a predisposing condition to multiple genetic
subtypes of BCP-ALLs.
To identify genes and pathways common to DS-ALLs, we have
generated a DS-ALL gene expression signature, exploiting the
Table 6. Clinical and diagnostic characteristics of patients with DS-ALL with high/medium expression of CRLF2 versus low/no expression
of CRLF2
No/low CRLF2 expression (n  20) High/medium CRLF2 expression (n  33) P
Sex 	 .999*
Male 11 17
Female 9 16
Age, y .004†
Mean (SE) 9.87 (1.21) 5.56 (0.67)
Median (range) 11.62 (1.74-18.7) 4.06 (1.99-20.22)
White blood cell count at diagnosis, cells/L .392†
Mean (SE) 41.6  109 (8.7  109) 39.8  (9.7  109)
Median (range) 23.9  109 (2.4-130  109) 18 930 (1.5-259  109)
JAK2 R683 mutations .008*
Yes 0 10
No 20 22
*According to Fisher exact test.
†According to Mann-Whitney U test.
Table 5. CRLF2 differentiating genes
Probe set ID Gene symbol Description Band Fold change
212592_at IGJ Immunoglobulin J chain 4q13.3 36.4
208303_s_at CRLF2 Cytokine receptor-like factor 2 isoform 1 Xp22.33 8.47
244871_s_at USP32 Ubiquitin specific protease 32 17q23.2 2.77
221523_s_at RRAGD Ras-related GTP binding D 6q15 0.551
208765_s_at HNRNPR 1p36.12 0.716
List of statistically significant differentiating genes (FDR 30%) between 8 DS-ALL samples with highest CRLF2 expression and 8 DS-ALL samples with lowest CRLF2
expression in AIEOP dataset. The fold change value is between the mean expression in the 2 groups.
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advantage of having several datasets. CRLF2 is 1 of the 3 genes
that most differentiates between DS-ALLs and non–DS-ALLs.
Confirming the expression of CRLF2 RNA and protein in DS-
ALLs and extending these observations to patients for whom array
data were not available, we observed increased expression of
CRLF2 in 62% of 53 patients with DS-ALL. These data are
corroborated by the recent report describing IGH@ translocations
or interstitial deletions upstream of CRLF2 in 5% of nonselected
childhood ALL, and in 35 (52%) of 68 DS-ALLs consecutively
enrolled in United Kingdom treatment protocols.13
We report that the interstitial deletion results in fusion transcript
in which the first noncoding exon of P2YR8 fuses to the coding
region of CRLF2, thereby driving CRLF2 expression by the P2YR8
promoter. A similar mechanism was reported in a single patient
with splenic lymphoma and P2YR8-SOX5 fusion34 and is reminis-
cent of the common SIL-SCL (STIL-TAL1) rearrangement in
T-ALL.35 Cloning of the genomic breakpoints is required to
determine whether, like SIL-SCL, the deletion is caused by aberrant
V(D)J activity.
Although we do not have genomic data for all CRLF2-
expressing samples, the FISH and RT-PCR results of 17 of
33 specimens overexpressing CRLF2, the inverse correlation
between CRLF2 and P2YRY8 expression, and the similar frequency
of CRLF2 overexpression in our and Russell et al’s13 2 independent
cohorts suggest that most, if not all, aberrant CRLF2 expression is
caused by genomic rearrangements.
CRLF2 dimerizes with IL7RA to form the receptor to thymic
stromal-derived lymphopoietin (TSLP), an epithelial-derived cyto-
kine that plays a role in inflammation and lymphoid develop-
ment.14,36-38 The expression of IL7RA on the leukemic blasts
suggests that some of the aberrantly expressed CRLF2 may interact
with IL7RA and form a TSLP receptor on the leukemic cells.
However, we also demonstrate that CRLF2 cooperates with Jak2 to
transform BaF3 cells lacking expression of IL7RA (Figure 5A and
supplemental Figure 5). This suggests that CRLF2 may act
independently of IL7RA, possibly through homodimerization
similar to other type I cytokine receptors.
We report an unusual cooperation between CRLF2 and ectopi-
cally expressed wt Jak2 in BaF3 cells, a phenomenon not observed
with other type I cytokine receptors such as erythropoietin receptor
(EPOR) or thrombopoietin receptor (TPOR). CRLF2 is an atypical
type I cytokine receptor that contains only one of the 2 “boxes” that
mediate binding of JAK enzymes and only one tyrosine in its
C-terminal domain. Hence it is a weak activator of JAK2.39 This
may explain the requirements for higher levels of Jak2 for
activation of the Jak/Stat pathway. Interestingly, the levels of
CRLF2 were higher in the presence of ectopically expressed wt or
mutated Jak2. Positive regulation of the expression of a type I
cytokine receptor by JAK2 and Tyk2 was previously reported.40-42
Thus one mechanism by which Jak2 may cooperate with CRLF2 is
by increasing the expression of the latter.
We observed 2 acquired events associated with the increased
expression of CRLF2. The most common event is activating “lym-
phoid” somatic mutation in JAK2. All DS-ALLs specimens with JAK2
mutations in our series and in the cohort reported by Russell et al13 had
aberrant expression of CRLF2, strongly implying that CRLF2 is the
cytokine receptor cooperating with R683 mutated JAK2. Indeed, in
BaF3 cytokine weaning assays, only the combination of CRLF2 and
mutated Jak2 led to a robust cytokine-independent growth, demonstrat-
ing for the first time that these 2 proteins cooperate in providing growth
and survival advantage.
Figure 5. Functional significance of CRLF2 expression. (A) Cytokine withdrawal assay of BaF3 and BaF3-CRLF2 cells infected with either empty vector (EV), mouse
FLAG-Jak2 wild-type (wt), or mouse FLAG-Jak2 R683S. Error bars represent SE. (B) Constitutive activation of the Jak/Stat5 pathway in BaF3 and BaF3-CRLF2 cells
expressing mouse FLAG-Jak2 wild-type (wt) or R683S, after 5 hours of cytokine deprivation. IL3 indicates cells harvested after 5 hours of interleukin-3 deprivation followed
by 15 minutes of interleukin-3 stimulation. (C) Effect of JAK inhibitor I on growth of BaF3 cells expressing Jak2 R683S and BaF3-CRLF2 cells expressing either wt Jak2 or
Jak2 R683S.
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The second less common event is an activating mutation in CRLF2.
Yoda et al43 reported an E40G activating somatic mutation in CRLF2 in
a single patient with adult BCP-ALL. We now found that 3 of the
33 patients with DS-ALL overexpressing CRLF2 have a somatic
mutation replacing phenylalanine in the juxtamembrane position 232 by
cysteine. This mutation caused constitutive phosphorylation of Stat5
associated with robust cytokine-independent growth of BaF3 cells
ectopically transduced with wt Jak2. Introduction of cysteines in this
region in the erythropoietin receptor, another type I cytokine receptor
signaling through JAK2, caused its constitutive activation by enhancing
ligand-independent dimerization.44
Although several scenarios may be possible, a reasonable model
(Figure 7) is that the overexpression of CRLF2 is the first event
occurring in approximately 60% of DS-ALL patients. The ex-
panded preleukemic clone then acquires additional genetic aberra-
tions, among them an activating mutation in JAK2 or CRLF2 or
thus far unidentified events that may involve the JAK/STAT
pathway. This model explains 3 key observations: (1) All samples
with mutated JAK2 and the only evaluable patient with mutated
CRLF2 also had aberrant CRLF2 expression. (2) Many CRLF2-
overexpressing samples do not have mutation in JAK2. (3) In one
reported patient,13 an aberrant CRLF2 genomic rearrangement was
present at diagnosis whereas mutant JAK2 was present only in the
relapse sample.
The most intriguing question is why there is a dramatic 10-fold
increase in genomic lesions causing CRLF2 overexpression in DS
(60% in DS-ALL compared with 5% in sporadic ALL) and how
this relates to trisomy 21. Only a single Hsa21 gene, SON, was
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Figure 6. Mutations of CRLF2 in patients with Down syndrome–associated acute lymphoblastic leukemia. (A) Example of sequences depicting the F232C in CRLF2.
The F232C (arrowed) is present at diagnosis but not in remission. The wild-type sequence denotes positions of both nucleotides and amino acids. (B) Expression of
CRLF2 F232C mutation. Examples of 2 patients: in one (i) both alleles, wild-type and mutated, are expressed, whereas in the other (ii) only the mutated allele is
expressed. (C) Schematic presentation of CRLF2. SP indicates signal peptide; EC, extracellular region; TM, transmembrane region; and Cy, cytoplasmic region. Numbers
indicate amino acid position. (D) Cytokine withdrawal assay of BaF3 cells stably expressing wild-type mouse FLAG-Jak2 that were transduced with either wild-type human
CRLF2 or human CRLF2 F232C. Error bars represent SE. (E) Constitutive activation of the Jak/Stat5 pathway in BaF3 cells expressing wild-type mouse FLAG-Jak2 and either
wild-type human CRLF2 (wt) or human CRLF2 F232C (F232C), after 5 hours of cytokine deprivation.
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included in the DS-ALL signature and it was only slightly (1.3)
up-regulated (supplemental Table 4). Indeed, we found no major
difference in the gene expression from the trisomic chromosome 21
between DS-ALL and HD-ALL (data not shown). Yet our data
suggest that DS-ALL and HD-ALL are to a great extent different
leukemias. There are obvious fundamental differences between
constitutional and acquired trisomy,45 such as the developmental
stage in which the trisomy occurs and the fact that a constitutional
trisomy is present both in the leukemia cells and in their
microenvironment.
Regardless of the role of the constitutional trisomy, our data
generate an intriguing hypothesis. We observe a significant enrich-
ment in DNA damage and repair genes in DS-ALL and identify
increased expression and clear “footprint” of BCL6 in these
leukemias. BCL6 regulates the germinal center B-cell maturation,
through its effects on the DNA damage response. Recent studies by
Duy et al46 suggest for the first time a role for BCL6 in BCP-ALL.
We speculate that DS may predispose to ALL through B-cell
lymphocytic specific genomic instability involving BCL6. The
signatures of BCL6 and the DNA damage response pathway may
be related to previous reports on impaired cellular response to DNA
damage in DS47 and to the increased prevalence of IgH@
chromosomal translocation in DS-ALL.13,48 At present, however, it
is impossible to determine whether the BCL6 signature precedes or
follows the CRLF2 rearrangements. As high expression of CRLF2
blocks B-cell differentiation,13 one cannot exclude the possibility
that it causes a developmental arrest of the preleukemic cell in
a stage in which BCL6 is active. Distinguishing between these
2 hypotheses will require the identification and study of preleuke-
mic cells in children with DS.
Finally, our data imply that therapeutics targeting JAK/STAT
signaling may be of potential benefit to the majority of DS-ALLs not
limited only to those with mutated JAK2.Although we demonstrate that
BaF3 cells coexpressing CRLF2 and mutated Jak2 are more susceptible
to JAK inhibitor l than cells transformed with BCR-ABL, they were
relatively resistant in comparison with cells transformed only with
mutated Jak2. This preliminary observation requires further testing in
primary leukemic cells. It may indicate that targeting other pathways
activated by CRLF2 or the use of anti–CRLF2-specific antibodies will
synergize with JAK2 inhibitors in treatment of DS-ALL and non–DS-
ALL with aberrant CRLF2 expression.
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Figure 7. CRLF2 in DS-ALL: a model. Increased
CRLF2 expression caused by genomic aberration is
followed by progression event consisting of activating
mutations in CRLF2, in JAK2, or other alterations in yet
unidentified kinases. The percentages in the figure are
approximations based on combination of the data in our
paper and in the paper by Russell et al.13
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